Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Gains from Sales and Divestitures (2018 - 2020)

Outlook Therapeutics (OTLK) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $109.0 as the latest value for Q2 2020.

  • Quarterly Gains from Sales and Divestitures changed N/A to $109.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $109.0 through Jun 2020, changed N/A year-over-year, with the annual reading at $4069.0 for FY2019, 96.14% down from the prior year.
  • Gains from Sales and Divestitures for Q2 2020 was $109.0 at Outlook Therapeutics, roughly flat from $109.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $105361.0 in Q3 2018, with the low at $109.0 in Q4 2019.
  • Average Gains from Sales and Divestitures over 3 years is $21951.4, with a median of $109.0 recorded in 2019.
  • Peak annual rise in Gains from Sales and Divestitures hit 96.14% in 2019, while the deepest fall reached 96.14% in 2019.
  • Over 3 years, Gains from Sales and Divestitures stood at $105361.0 in 2018, then plummeted by 99.9% to $109.0 in 2019, then changed by 0.0% to $109.0 in 2020.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $109.0, $109.0, and $109.0 for Q2 2020, Q1 2020, and Q4 2019 respectively.